Atypical Antipsychotic Drugs Directly Impair Insulin Action in Adipocytes: Effects on Glucose Transport, Lipogenesis, and Antilipolysis

Vestri, Helliner S; Maianu, Lidia; Moellering, Douglas R.; Garvey, W. Timothy

doi:10.1038/sj.npp.1301366

Cited by 40 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These effects have been attributed/hypothesized to be because of various mechanisms as below: olanzapine promotes fat deposition by directly affecting adipocyte function[6] ; it may increase triglyceride levels[7] : it may cause body weight gain and hyperphagia by altering appetite signalling in the brain and periphery. [8] ; it disturbs the metabolism by making the body take preferentially its energy from fat (instead of privileging carbohydrates).…”

Section: Discussionmentioning

confidence: 99%

Emphysematous pancreatitis predisposed by Olanzapine

Samanta¹,

Samanta²,

Banik³

et al. 2014

Indian J Anaesth

View full text Add to dashboard Cite

A 32-year-old male presented to our intensive care unit with severe abdominal pain and was diagnosed as acute pancreatitis after 2 months of olanzapine therapy for bipolar disorder. His serum lipase was 900 u/L, serum triglyceride 560 mg/dL, and blood sugar, fasting and postprandial were 230 and 478 mg/dL, respectively on admission. Contrast enhanced computed tomography (CECT) of abdomen was suggestive of acute pancreatitis. Repeat CECT showed gas inside pancreas and collection in peripancreatic area and patient underwent percutaneous drainage and antibiotics irrigation through the drain into pancreas. We describe the rare case of emphysematous pancreatitis due to development of diabetes, hypertriglyceridemia and immunosuppression predisposed by short duration olanzapine therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Emphysematous pancreatitis predisposed by Olanzapine

Samanta¹,

Samanta²,

Banik³

et al. 2014

Indian J Anaesth

View full text Add to dashboard Cite

show abstract

“…The prediction of treatment side effects, while highly important, is likely among the most challenging goals for neurophysio logical biomarkers in schizophrenia. This is because some side effects may be partly due to non neural mechanisms (e.g., atypical antipsychotics modulating insulin effects on adipocytes 157 ), and some of the most serious side effects, such as neuroleptic malignant syndrome 158 , are relatively rare.…”

Section: Predictive Biomarkers Of Medication Side Effectsmentioning

confidence: 99%

Candidate biomarkers in psychiatric disorders: state of the field

et al. 2023

View full text Add to dashboard Cite

The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can aid in objectively diagnosing patients and providing individualized treatment recommendations. Here we review and critically evaluate the evidence for the most promising biomarkers in the psychiatric neuroscience literature for autism spectrum disorder, schizophrenia, anxiety disorders and post‐traumatic stress disorder, major depression and bipolar disorder, and substance use disorders. Candidate biomarkers reviewed include various neuroimaging, genetic, molecular and peripheral assays, for the purposes of determining susceptibility or presence of illness, and predicting treatment response or safety. This review highlights a critical gap in the biomarker validation process. An enormous societal investment over the past 50 years has identified numerous candidate biomarkers. However, to date, the overwhelming majority of these measures have not been proven sufficiently reliable, valid and useful to be adopted clinically. It is time to consider whether strategic investments might break this impasse, focusing on a limited number of promising candidates to advance through a process of definitive testing for a specific indication. Some promising candidates for definitive testing include the N170 signal, an event‐related brain potential measured using electroencephalography, for subgroup identification within autism spectrum disorder; striatal resting‐state functional magnetic resonance imaging (fMRI) measures, such as the striatal connectivity index (SCI) and the functional striatal abnormalities (FSA) index, for prediction of treatment response in schizophrenia; error‐related negativity (ERN), an electrophysiological index, for prediction of first onset of generalized anxiety disorder, and resting‐state and structural brain connectomic measures for prediction of treatment response in social anxiety disorder. Alternate forms of classification may be useful for conceptualizing and testing potential biomarkers. Collaborative efforts allowing the inclusion of biosystems beyond genetics and neuroimaging are needed, and online remote acquisition of selected measures in a naturalistic setting using mobile health tools may significantly advance the field. Setting specific benchmarks for well‐defined target application, along with development of appropriate funding and partnership mechanisms, would also be crucial. Finally, it should never be forgotten that, for a biomarker to be actionable, it will need to be clinically predictive at the individual level and viable in clinical settings.

show abstract

Schizophrenia Outside the Brain

Valença

Smith

2022

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Atypical Antipsychotic Drugs Directly Impair Insulin Action in Adipocytes: Effects on Glucose Transport, Lipogenesis, and Antilipolysis

Cited by 40 publications

References 6 publications

Emphysematous pancreatitis predisposed by Olanzapine

Emphysematous pancreatitis predisposed by Olanzapine

Candidate biomarkers in psychiatric disorders: state of the field

Schizophrenia Outside the Brain

Contact Info

Product

Resources

About